Targeting a newly-discovered adhesion checkpoint

The PointGuard first-in-man clinical trial is expected to provide valuable efficacy & mechanistic biomarkers data. It is a randomized, blinded, placebo-controlled dose-ranging study evaluating the safety, tolerability, PK and PD of subcutaneous single and multiple ascending doses of IW-601 in healthy subjects.